The Sepranolone Story
Sepranolone was originally developed for the treatment of PMDD by Professor Torbjörn Bäckström, Asarina’s CSO and Founder and Senior Professor in Obstetrics and Gynecology, University of Umeå.
“I first came to research ALLO through the study of premenstrual disorders, but it became clear to me quickly just how potent and extensive the effect of ALLO is. In the coming years I think we’ll see new diagnostic and therapeutic links emerge between GABA-active neurosteroids and a range of conditions.”
Bäckström has published extensively on ALLO’s effect on a number of Central Nervous System disorders. His research has included highly-cited work on ALLO’s effects on:
- epilepsy (1)
- overeating (2)
- balance (3)
- mood disorders (4)(5)
- cognition (6)
1. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle ion to epilepsy and anaesthesia. (1976, Bäckström et al.)
2. Allopregnanolone involvement in feeding regulation, overeating and obesity (Jan 2018, Bäckström et al.)
3. The influence of premenstrual symptoms on postural balance and kinesthesia during the menstrual cycle (Dec 2003, Bäckström et al.)
4. Allopregnanolone and mood disorders (Feb 2014, Bäckström et al.)
5. Sex steroid induced negative mood may be explained by the paradoxical effect mediated by GABAA modulators (Sept 2009 Bäckström et al.)
6. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women (2006, Timby et al Psychopharmacology)